Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model
Introduction: Generic pharmaceuticals account for the majority of the $359 billion US pharmaceutical market, including for cardiology drugs. Amidst a lack of price transparency and administrative inefficiencies, generic drug prices are high, causing an undue burden on patients.Methods: We identified...
Main Authors: | Aparna Narendrula, Jacob Lang, Elias Mossialos |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1179253/full |
Similar Items
-
An empirical study of the impact of generic drug competition on drug market prices in China
by: Chen Yina, et al.
Published: (2023-05-01) -
Generic drugs: benefit/risk ratio
by: E. A. Ushkalova, et al.
Published: (2021-12-01) -
Generic Medicine Pricing Policies in Europe: Current Status and Impact
by: Pieter Dylst, et al.
Published: (2010-03-01) -
ASSESSMENT OF QUALITY OF GENERICS IN CARDIOLOGY: REALITY AND POSSIBILITIES
by: V. V. Yakusevich
Published: (2015-12-01) -
Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa?
by: Varsha Bangalee, et al.
Published: (2016-10-01)